Gastrointestinal Cancer
From the Journals
Neoantigen profiling predicts response to immunotherapy
In antitumor immunity and immunotherapy, quality and fitness count.Specifically, the quality and fitness of neoantigens – tumor-specific mutated...
Conference Coverage
Nivolumab may extend survival in HCC patients
WASHINGTON – About 20% of patients achieved an objective remission that included complete responses in all subgroups of patients.
Conference Coverage
Endoscopic therapy effective for early cancer in Barrett’s esophagus
ORLANDO – Endoscopic therapy is as effective in Barrett’s esophagus patients with early cancer as in those with high-grade dysplasia, according to...
Conference Coverage
Barrett’s esophagus length predicts disease progression
ORLANDO – Barrett’s esophagus length is a readily accessible endoscopic marker for disease progression, and it could aid in risk stratification...
Feature
Biosimilars poised to save $54 billion over the next decade
But uncertainty points to savings ranging from $24 billion to $150 billion.
From the Journals
Survey colonoscopy outpatients to flag high cancer risk
Paper and electronic surveys together identified patients in need of referral for genetic testing for colorectal cancer risk.
Conference Coverage
Pilot study: Novel spray powder stops GI bleeding
ORLANDO –
Conference Coverage
Worse survival with cetuximab plus chemo for CRC liver mets
MADRID – Adding cetuximab as either neoadjuvant or adjuvant treatment resulted in significantly worse survival compared with perioperative...
From the Journals
Dabigatran, rivaroxaban linked to slight increase in GI bleeding risk
Overall, the risk of major bleeds associated with NOACs was similar to the risk with conventional anticoagulants.
Conference Coverage
Robot-assisted abdominoperineal resection outperforms open or laparoscopic surgery for rectal cancers
Patients assigned to robotic-assisted surgery had a total complication rate of 10.4%, compared with 18.8% for patients assigned to laparoscopy and...
News
FDA approves pembrolizumab for gastric and GEJ adenocarcinoma
The checkpoint inhibitor is approved for patients with advanced tumors containing PD-L1 and where the disease is progressing on or after two or...